⚲
|
Intellia Therapeutics Inc | |
---|---|
Ticker | NTLA |
CIK # | 0001652130 |
CUSIP | 45826J105 |
Sector | Life Sciences |
Industry | In Vitro & In Vivo Diagnostic Substances |
Phone | 8572856200 |
Address | 130 Brookline Street Suite 201 Cambridge, MA 02139 |
Source | [EDGAR] |
Market Cap, 13F ($) |
---|
Business |
---|
We are a leading genome editing company focused on developing curative therapeutics utilizing a biological tool known as CRISPR/Cas9, which stands for Clustered, Regularly Interspaced Short Palindromic Repeats ("CRISPR")/CRISPR associated 9 ("Cas9"). This is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid ("DNA"). We believe that CRISPR/Cas9 technology has the potential to transform medicine by editing disease-associated genes with a single treatment course, and that it can also be used to create novel engineered cell therapies that can replace a patient's diseased cells or effectively target various cancers and autoimmune diseases. We are leveraging our leading scientific expertise, clinical development experience and intellectual property ("IP") position to unlock a broad set of therapeutic applications for CRISPR/Cas9 genome editing and to develop a potential new class of therapeutic products. Our mission is to build a company to develop curative genome editing treatments that can positively transform the lives of people living with severe and life-threatening disease. We believe we can deliver on our mission and provide long-term benefits for all of our stakeholders by focusing on four key elements - - Develop curative CRISPR/Cas9 based medicines; |
CIK | Filing | 2011 - 2023 |
---|---|---|
[0001652130] | 10-K | |
[0001652130] | 10-Q | |
[0001652130] | 3 | |
[0001652130] | 4 | |
[0001652130] | 5 | |
[0001652130] | 8-K | |
[0001652130] | D | |
[0001652130] | SC 13D | |
[0001652130] | SC 13G |